The Trump administration has introduced TrumpRx.gov, a new platform designed to reduce prescription drug prices in the United States by aligning them with the lowest prices found in developed countries. According to NS3.AI, the initiative primarily targets uninsured and cash-paying patients, offering substantial discounts on widely used medications, including GLP-1 agonists, through manufacturer coupons. However, critics have raised concerns that the platform addresses only a limited segment of the market and may simply rebrand existing discounts without tackling deeper systemic issues in drug pricing. Additionally, questions persist regarding the sustainability of the platform and its potential impact on broader drug pricing reforms.